Volume 3, Issue 4 (2-2021)
2021, 3(4): 0-0 |
Back to browse issues page
Ethics code: IR.MEDILAM.REC.1398.185
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Gheysarzadeh A, Bakhtiyari S, Mofid M R. Chemosensitization of pancreatic ductal adenocarcinoma by Insulin-like growth factor binding protein 3 (IGFBP-3). Journal title 2021; 3 (4)
URL: http://newresearch.medilam.ac.ir/article-1-811-en.html
URL: http://newresearch.medilam.ac.ir/article-1-811-en.html
Clinical Microbiology Research Center, Ilam University of Medical sciences, Ilam, Iran
Abstract: (2666 Views)
risk factor for pancreatic cancer is diabetes. It is quite clear that people with diabetes are at risk for pancreatic cancer, the cause of which has not yet been determined (4, 5). These people with diabetes often have type 2 diabetes, and it is not yet known whether type 1 diabetes is a risk factor for pancreatic cancer. In addition, chronic pancreatitis, liver cirrhosis and Helicobacter pylori are also mentioned as risk factors for pancreatic cancer (6-8).
Despite the many efforts that have been made to treat pancreatic cancer, there is still no specific treatment that works well. For the treatment of pancreatic cancer, like other cancers, chemotherapy after surgery has been suggested as a second way (9). But unfortunately in most cases chemotherapy will be associated with significant resistance. So that the treatment of this disease faces a huge challenge. Thus, a large proportion of studies today have focused on the sensitization of pancreatic tumors to chemotherapy.
One of the most important strategies to increase sensitivity to chemotherapy is the use of proteins. A pilot study by our research team shows that the TMEM-219 cell death receptor, which activates the IGFBP-3-dependent cell death pathway, increases with doxorubicin in cell-treated conditions. Accordingly, this study attempts to sensitize pancreatic tumor cells to chemotherapy using exogenous IGFBP-3. Obviously, if the right result is achieved, it will be worthwhile to develop new therapies based on chemotherapy.
Despite the many efforts that have been made to treat pancreatic cancer, there is still no specific treatment that works well. For the treatment of pancreatic cancer, like other cancers, chemotherapy after surgery has been suggested as a second way (9). But unfortunately in most cases chemotherapy will be associated with significant resistance. So that the treatment of this disease faces a huge challenge. Thus, a large proportion of studies today have focused on the sensitization of pancreatic tumors to chemotherapy.
One of the most important strategies to increase sensitivity to chemotherapy is the use of proteins. A pilot study by our research team shows that the TMEM-219 cell death receptor, which activates the IGFBP-3-dependent cell death pathway, increases with doxorubicin in cell-treated conditions. Accordingly, this study attempts to sensitize pancreatic tumor cells to chemotherapy using exogenous IGFBP-3. Obviously, if the right result is achieved, it will be worthwhile to develop new therapies based on chemotherapy.
Subject:
General
Received: 2019/10/12 | Accepted: 2020/01/15 | Published: 2021/02/28
Received: 2019/10/12 | Accepted: 2020/01/15 | Published: 2021/02/28
Send email to the proposal executer
| Rights and permissions | |
 | This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
